Stock Analysis

Nakanishi First Quarter 2025 Earnings: EPS: JP¥5.22 (vs JP¥39.67 in 1Q 2024)

TSE:7716
Source: Shutterstock

Nakanishi (TSE:7716) First Quarter 2025 Results

Key Financial Results

  • Revenue: JP¥18.5b (up 2.1% from 1Q 2024).
  • Net income: JP¥440.0m (down 87% from 1Q 2024).
  • Profit margin: 2.4% (down from 19% in 1Q 2024).
  • EPS: JP¥5.22 (down from JP¥39.67 in 1Q 2024).
We've discovered 2 warning signs about Nakanishi. View them for free.
earnings-and-revenue-growth
TSE:7716 Earnings and Revenue Growth May 13th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nakanishi Earnings Insights

Looking ahead, revenue is forecast to grow 5.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Japan.

Performance of the Japanese Medical Equipment industry.

The company's shares are down 3.0% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Nakanishi.

Valuation is complex, but we're here to simplify it.

Discover if Nakanishi might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.